Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first & second-line Abiraterone & Enzalutamide

Journal of Clinical Oncology

Volumn 35, Issue 19, 2017, Pages 2149-2156

  Antonarakis, Emmanuel S ^a   Lu, Changxue ^a   Luber, Brandon ^a   Wang, Hao ^a   Chen, Yan ^a   Zhu, Yezi ^a   Silberstein, John L ^a   Taylor, Maritza N ^a   Maughan, Benjamin L ^a   Denmeade, Samuel R ^a   Pienta, Kenneth J ^a   Paller, Channing J ^a   Carducci, Michael A ^a   Eisenberger, Mario A ^a   Luo, Jun ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; BIOLOGICAL MARKER; ENZALUTAMIDE; MESSENGER RNA; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; ISOPROTEIN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PHENYLTHIOHYDANTOIN;

AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CLINICAL TRIAL; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; COHORT ANALYSIS; DISEASE FREE SURVIVAL; GENETICS; METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME;

AGED; ANDROSTENES; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; KALLIKREINS; MALE; NEOPLASM METASTASIS; PHENYLTHIOHYDANTOIN; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 85019242735     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.70.1961     Document Type: Article

References (13)

1. Antonarakis ES, Armstrong AJ, Dehm SM, et al: Androgen receptor variant-driven prostate cancer: Clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis 19:231-241, 2016.
2. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011.
3. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012.
4. Antonarakis ES, Lu C, Wang H, et al: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028-1038, 2014.
5. Steinestel J, Luedeke M, Arndt A, et al: Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 18632/oncotarget.3925 [epub ahead of print on April 23, 2015].
6. Scher HI, Lu D, Schreiber NA, et al: Association of AR-V7 on circulating tumor cells as a treatmentspecific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2: 1441-1449, 2016.
7. Antonarakis ES, Lu C, Luber B, et al: Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castrationresistant prostate cancer. JAMA Oncol 1:582-591, 2015.
8. Onstenk W, Sieuwerts AM, Kraan J, et al: Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol 68:939-945, 2015.
9. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009.
10. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148-1159, 2008.
11. Miyamoto DT, Zheng Y, Wittner BS, et al: RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science 349:1351-1356, 2015.
12. Bernemann C, Schnoeller TJ, Luedeke M, et al: Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration-resistant prostate cancer. Eur Urol 71:1-3, 2017.
13. Scher HI, Morris MJ, Stadler WM, et al: Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34:1402-1418, 2016.